社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
ImmunityBio, Inc.(IBRX)
盘后
8.41
0.02
+0.24%
19:59 EDT
8.39
+0.57
+7.29%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
瞪羚侃新股
·
02-25
打爆空头！PD-1挑战者，今年5倍了
创新药公司如何打爆空头？Immunity Bio正在“手把手”教你如何做到。 拥有已商业化IL-15超级激动剂ANKTIVA的Immunity Bio（IBRX）在2026年以来经历了暴涨，从年初的2美元/股上涨至如今的11.55美元/股，年内累计涨幅高达483.33%。 过去一年这家公司是被空头最喜爱的生物科技标的之一，但1月21日有报道指出IBRX反弹已经让空头们账面浮亏4.92亿美元，如今看来这一数字只会更多。 IBRX到底经历了什么又或是做出了什么改变，让自身市值实现大反转，如今公司的市值已经来到了118.75亿美元，这显然是一个值得细品的课题。 01 一扫2025阴霾，2026疯狂输出 IBRX近两年核心价值在于IL-15激动剂ANKTIVA在非肌层浸润性膀胱癌（NMIBC）和转移性非小细胞肺癌（NSCLC）两大适应症赛道。 2025年公司价值受到压制主要基于几个方面： 1）早在2024年4月FDA批准了ANKTIVA获批了联合卡介苗（BCG）用于BCG无应答的非肌层浸润性膀胱癌（NMIBC）伴原位癌（CIS），但商业化早期放量不及预期，上市首年仅取得3000万美元出头的收入，显著低于同适应症药物的上市放量速度，这一困境与BCG在美国短缺有关（IBRX已与印度血清研究所合作解决BCG供给替代问题）； 2）早在2024Q1提交乳头状NMIBC（无CIS）的sBLA，2025年收到FDA完整回复函（CRL）或需要额外数据； 3）2025年9月FDA强生批准BCG无应答、携带CIS的成人NMIBC患者，对ANKTIVA形成显著竞争压力； 4）ANKTIVA收入迟迟未能放大对公司经营造成巨大压力，2025年前三季度单季收入分别为1651万美元、2642万美元、3206万美元，但单季归母净亏损仍达1.3亿美元、9257万美元和6727万美元，同时公司现金储备显得捉襟见肘（2
打爆空头！PD-1挑战者，今年5倍了
回复
评论
点赞
1
编组 21备份 2
分享
举报
栲栲
·
2025-06-03
$ImmunityBio, Inc.(IBRX)$
11
$ImmunityBio, Inc.(IBRX)$ 11
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
美股投资网
·
2024-10-26
不眠夜！22小时都可以交易美股！纽约证券官宣！
美国纽约证券交易所周五宣布，计划将其全电子交易所的交易时间延长至每天 22 小时。根据新计划，纽约证券交易所 Arca 电子交易所的交易将于工作日凌晨 1:30 开始，并于美国东部时间晚上 11:30 结束，但须经监管机构批准。纽约证券交易所计划向美国证券交易委员会提交延长交易时间的最新规则。据美股投资网获悉，这里所说的延长交易时间，依然属于俗称的美股盘前、盘后交易。在正常交易时段（美东9点半-16点）之外进行美股交易，需要经过监管的批准。纽交所表示，延长交易时段的清算将继续由DTCC（美国存款信托与清算公司）进行，后者近期也已经宣布延长运营时段。美国纽约证券交易所（NYSE）是全球最大的证券交易所，也是美股投资网CEO兼创始人Ken之前的雇主，NYSE Arca 是买卖交易所交易基金和 8,000 多种美国上市证券的顶级平台。NYSE的母公司ICE洲际交易所表示，所有在美国上市的股票、ETF 和封闭式基金都将在电子交易所的 22 小时内开放交易。“纽约证交所市场主管凯文-泰瑞尔（Kevin Tyrrell）在一份声明中说："纽约证券交易所将美股交易时间延长至每周 5 天每天 22 小时的举措，凸显了美国资本市场的实力以及全球对我们上市证券日益增长的需求。“作为美国资本市场的管理者，纽约证券交易所很高兴能引领全球时区的投资者在交易所交易我们在美国上市的公司和基金"。图片纽约证券交易所简介市值：NYSE的上市公司总市值通常高于任何其他交易所，包括纳斯达克（NASDAQ）和其他国际交易所。交易量：NYSE的日交易量和交易活动也非常活跃，尽管纳斯达克在某些时候的交易量可能超过NYSE。历史：NYSE成立于1817年，拥有悠久的历史，是全球最古老的证券交易所之一。全球影响力：由于其规模和影响力，NYSE在全球金融市场中扮演着重要角色，许多国际公司选择在此上市。美股周五收盘涨跌不一。
不眠夜！22小时都可以交易美股！纽约证券官宣！
回复
评论
点赞
1
编组 21备份 2
分享
举报
牛唐
·
2024-04-30
正股跟随期权走，
$ImmunityBio, Inc.(IBRX)$
连续两天暴涨40%+，上周五放出5月3日到期的，6美元的看涨期权巨量，周一股价也是跟进上涨。
$Cyclacel Pharmaceuticals(CYCC)$
$哔哩哔哩(BILI)$
正股跟随期权走，$ImmunityBio, Inc.(IBRX)$ 连续两天暴涨40%+，上周五放出5月3日到期的，6美元的看涨期权巨量，周一股价也是跟进...
回复
评论
点赞
1
编组 21备份 2
分享
举报
富悦守财哥
·
2024-04-29
#守财哥的复盘日记20240427
$ImmunityBio, Inc.(IBRX)$
上周做对了票，判断也基本正确，却没赚到应该赚到的利润[流泪] [流泪] [流泪] 究其原因，终归贪念。跳空上涨后，做了坠落天使策略，出场虽早了点，毕竟是按交易计划进行。在震荡中空仓，忍不住做了其他票，等到天使👼回归时却没有了仓位，又舍不得出其他仓位，错过完美的赚大钱机会... 呜呼！交易的尽头，是耐心，是等待，是经得起诱惑的决绝...
#守财哥的复盘日记20240427 $ImmunityBio, Inc.(IBRX)$ 上周做对了票，判断也基本正确，却没赚到应该赚到的利润[流泪] [流...
回复
评论
点赞
1
编组 21备份 2
分享
举报
Recyce
·
2024-04-30
20240430 Hea左几日，又睇睇个市先，SPX 明显系4月19日星期出左个底，4月22日ROC 2 系过去30日新高，算系一个入场信号，4月25日做左higher low ，跳跌低开即日补裂口兼高收，有明显大成交，如果冷静可以睇到呢个系几明显信号(但我都无睇到)，4月26日继续跳升亦无补裂口，呢此可见呢个反弹十分劲，寻晚亦企稳20EMA上，可以考虑积极入场。个股方面，IBRX系开市有大成交，于是想搏短炒大升，$10入但$9.5中止蚀走，但因为睇到有D机会可能再爆上，于是再入货，$9入场，止蚀系$7.5，重申呢D炒法，输既幅度一定系自己接受到、训得著，唔系下下训身去。而家我既杠杆系数系1.52，算系满仓有突了。
$ImmunityBio, Inc.(IBRX)$
$纳指100ETF(QQQ)$
$标普500(.SPX)$
20240430 Hea左几日，又睇睇个市先，SPX 明显系4月19日星期出左个底，4月22日ROC 2 系过去30日新高，算系一个入场信号，4月25日做...
回复
评论
点赞
1
编组 21备份 2
分享
举报
朝朝1030
·
2024-04-30
$ImmunityBio, Inc.(IBRX)$
$ImmunityBio, Inc.(IBRX)$
$ImmunityBio, Inc.(IBRX)$ $ImmunityBio, Inc.(IBRX)$
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
朝朝1030
·
2024-04-30
$ImmunityBio, Inc.(IBRX)$
$ImmunityBio, Inc.(IBRX)$
$ImmunityBio, Inc.(IBRX)$ $ImmunityBio, Inc.(IBRX)$
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
朝朝1030
·
2024-04-30
$ImmunityBio, Inc.(IBRX)$
$ImmunityBio, Inc.(IBRX)$
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
朝朝1030
·
2024-04-29
$ImmunityBio, Inc.(IBRX)$
买入 8.88
$ImmunityBio, Inc.(IBRX)$ 买入 8.88
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
公司概况
公司名称
ImmunityBio, Inc.
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.immunitybio.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
ImmunityBio, Inc.于2002年10月7日在伊利诺伊州ZelleRx Corporation公司的名义下注册成立，于2010年1月22日，公司更名为Conkwest股份有限公司。ImmunityBio是一家领先的晚期免疫治疗公司，可激活先天和适应性免疫系统，以治疗肿瘤学和传染病领域内严重未满足的需求。公司是一家领先的临床剂型的现成自然杀伤细胞疗法生产商，记忆NK细胞，连同抗体细胞因子融合蛋白、白蛋白结合化学免疫调节剂和疫苗载体的综合平台。通过结合这些NK、巨噬细胞和T细胞激活平台，该公司相信ImmunityBio在免疫治疗领域处于领先地位，具有跨越多种肿瘤类型和传染病的后期临床开发。
02-24
年度报告
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
02-24
关联方拟减持公告
Form 144 | ImmunityBio董事Christobel Selecky拟减持25000股，总价约21.75万美元
Form 144 | ImmunityBio董事Christobel Selecky拟减持25000股，总价约21.75万美元
02-23
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
02-18
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
01-26
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
01-21
关联方拟减持公告
Form 144 | IMMUNITYBIO董事 Christobel Selecky 拟减持25000股，总价约13.8万美元
Form 144 | IMMUNITYBIO董事 Christobel Selecky 拟减持25000股，总价约13.8万美元
01-20
关联方拟减持公告
Form 144 | ImmunityBio高管兼董事 Simon Barry J.拟减持571967股，总价约590万美元
Form 144 | ImmunityBio高管兼董事 Simon Barry J.拟减持571967股，总价约590万美元
01-16
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
01-15
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
01-14
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-12-24
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-12-16
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-12-12
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-11-05
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-11-05
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
分时
5日
日
周
月
数据加载中...
最高
8.91
今开
8.21
量比
1.46
最低
8.20
昨收
7.82
换手率
9.11%
热议股票
{"pagemeta":{"title":"ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ImmunityBio, Inc.(IBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ImmunityBio, Inc.,IBRX,ImmunityBio, Inc.股票,ImmunityBio, Inc.股票老虎,ImmunityBio, Inc.股票老虎国际,ImmunityBio, Inc.行情,ImmunityBio, Inc.股票行情,ImmunityBio, Inc.股价,ImmunityBio, Inc.股市,ImmunityBio, Inc.股票价格,ImmunityBio, Inc.股票交易,ImmunityBio, Inc.股票购买,ImmunityBio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ImmunityBio, Inc.(IBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"IBRX","data":{"stockData":{"symbol":"IBRX","market":"US","secType":"STK","nameCN":"ImmunityBio, Inc.","latestPrice":8.39,"timestamp":1773432000000,"preClose":7.82,"halted":0,"volume":30623231,"hourTrading":{"tag":"盘后","latestPrice":8.41,"preClose":8.39,"latestTime":"19:59 EDT","volume":244004,"amount":2049090.2234,"timestamp":1773446386816,"change":0.02,"changeRate":0.002384,"amplitude":0.008284},"delay":0,"changeRate":0.0728900255754476,"floatShares":336000000,"shares":1027999999,"eps":-0.382011,"marketStatus":"休市中","change":0.57,"latestTime":"03-13 16:00:00 EDT","open":8.21,"high":8.91,"low":8.2,"amount":259507904.73512697,"amplitude":0.090793,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.382011,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1773648000000},"marketStatusCode":7,"adr":0,"listingDate":1438056000000,"exchange":"NASDAQ","adjPreClose":7.82,"preHourTrading":{"tag":"盘前","latestPrice":8.21,"preClose":7.82,"latestTime":"09:29 EDT","volume":773797,"amount":6295694.8013805,"timestamp":1773408599999,"change":0.39,"changeRate":0.049872,"amplitude":0.054987},"postHourTrading":{"tag":"盘后","latestPrice":8.41,"preClose":8.39,"latestTime":"19:59 EDT","volume":244004,"amount":2049090.2234,"timestamp":1773446386816,"change":0.02,"changeRate":0.002384,"amplitude":0.008284},"volumeRatio":1.4575739414879982,"optionData":{"bulkOrders":[{"symbol":"IBRX","call":true,"expireDate":1784260800000,"strike":"9.0","timestamp":1773337806311,"price":1.66,"volume":3500,"amount":581000,"type":"-"},{"symbol":"IBRX","call":false,"expireDate":1784260800000,"strike":"9.0","timestamp":1773337806311,"price":2.81,"volume":3500,"amount":983500,"type":"+"}]},"impliedVol":1.3599,"impliedVolPercentile":0.8247},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.536629899015808","cardData":[{"tweetId":"536629899015808","author":{"authorId":"3551780874549647","idStr":"3551780874549647","name":"瞪羚侃新股","avatar":"https://static.tigerbbs.com/3c51d12626fd16c5502d8d7a95cad382","userType":1,"introduction":"","crmLevel":5,"crmLevelSwitch":0,"fanSize":593,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"打爆空头！PD-1挑战者，今年5倍了","digest":"创新药公司如何打爆空头？Immunity Bio正在“手把手”教你如何做到。 拥有已商业化IL-15超级激动剂ANKTIVA的Immunity Bio（IBRX）在2026年以来经历了暴涨，从年初的2美元/股上涨至如今的11.55美元/股，年内累计涨幅高达483.33%。 过去一年这家公司是被空头最喜爱的生物科技标的之一，但1月21日有报道指出IBRX反弹已经让空头们账面浮亏4.92亿美元，如今看来这一数字只会更多。 IBRX到底经历了什么又或是做出了什么改变，让自身市值实现大反转，如今公司的市值已经来到了118.75亿美元，这显然是一个值得细品的课题。 01 一扫2025阴霾，2026疯狂输出 IBRX近两年核心价值在于IL-15激动剂ANKTIVA在非肌层浸润性膀胱癌（NMIBC）和转移性非小细胞肺癌（NSCLC）两大适应症赛道。 2025年公司价值受到压制主要基于几个方面： 1）早在2024年4月FDA批准了ANKTIVA获批了联合卡介苗（BCG）用于BCG无应答的非肌层浸润性膀胱癌（NMIBC）伴原位癌（CIS），但商业化早期放量不及预期，上市首年仅取得3000万美元出头的收入，显著低于同适应症药物的上市放量速度，这一困境与BCG在美国短缺有关（IBRX已与印度血清研究所合作解决BCG供给替代问题）； 2）早在2024Q1提交乳头状NMIBC（无CIS）的sBLA，2025年收到FDA完整回复函（CRL）或需要额外数据； 3）2025年9月FDA强生批准BCG无应答、携带CIS的成人NMIBC患者，对ANKTIVA形成显著竞争压力； 4）ANKTIVA收入迟迟未能放大对公司经营造成巨大压力，2025年前三季度单季收入分别为1651万美元、2642万美元、3206万美元，但单季归母净亏损仍达1.3亿美元、9257万美元和6727万美元，同时公司现金储备显得捉襟见肘（2","plainDigest":"创新药公司如何打爆空头？Immunity Bio正在“手把手”教你如何做到。 拥有已商业化IL-15超级激动剂ANKTIVA的Immunity Bio（IBRX）在2026年以来经历了暴涨，从年初的2美元/股上涨至如今的11.55美元/股，年内累计涨幅高达483.33%。 过去一年这家公司是被空头最喜爱的生物科技标的之一，但1月21日有报道指出IBRX反弹已经让空头们账面浮亏4.92亿美元，如今看来这一数字只会更多。 IBRX到底经历了什么又或是做出了什么改变，让自身市值实现大反转，如今公司的市值已经来到了118.75亿美元，这显然是一个值得细品的课题。 01 一扫2025阴霾，2026疯狂输出 IBRX近两年核心价值在于IL-15激动剂ANKTIVA在非肌层浸润性膀胱癌（NMIBC）和转移性非小细胞肺癌（NSCLC）两大适应症赛道。 2025年公司价值受到压制主要基于几个方面： 1）早在2024年4月FDA批准了ANKTIVA获批了联合卡介苗（BCG）用于BCG无应答的非肌层浸润性膀胱癌（NMIBC）伴原位癌（CIS），但商业化早期放量不及预期，上市首年仅取得3000万美元出头的收入，显著低于同适应症药物的上市放量速度，这一困境与BCG在美国短缺有关（IBRX已与印度血清研究所合作解决BCG供给替代问题）； 2）早在2024Q1提交乳头状NMIBC（无CIS）的sBLA，2025年收到FDA完整回复函（CRL）或需要额外数据； 3）2025年9月FDA强生批准BCG无应答、携带CIS的成人NMIBC患者，对ANKTIVA形成显著竞争压力； 4）ANKTIVA收入迟迟未能放大对公司经营造成巨大压力，2025年前三季度单季收入分别为1651万美元、2642万美元、3206万美元，但单季归母净亏损仍达1.3亿美元、9257万美元和6727万美元，同时公司现金储备显得捉襟见肘（2","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1772032246763,"gmtModify":1772032819347,"symbols":["JNJ","IBRX","CGON"],"themeIds":["bbff91dc17c14a06a84c8b103cf4e290"],"popularizeThemeFlag":false,"imageCount":7,"images":[{"url":"https://static.tigerbbs.com/429a7baafe21156b0644cf26778b26f9","width":"640","height":"273"}],"repostCount":0,"viewCount":497,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/536629899015808","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4922,"displayRows":4,"foldSize":0,"authorId":"3551780874549647"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.442084796453416","cardData":[{"tweetId":"442084796453416","author":{"authorId":"4211078412307832","idStr":"4211078412307832","name":"栲栲","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":3,"crmLevelSwitch":0,"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/IBRX\">$ImmunityBio, Inc.(IBRX)$</a> 11","plainDigest":"$ImmunityBio, Inc.(IBRX)$ 11","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1748953522717,"gmtModify":1748953523586,"symbols":["IBRX"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":2047,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/442084796453416","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":26,"displayRows":4,"foldSize":0,"authorId":"4211078412307832"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.364145188810816","cardData":[{"tweetId":"364145188810816","author":{"authorId":"3478213283465426","idStr":"3478213283465426","name":"美股投资网","avatar":"https://static.tigerbbs.com/a1bfd2cf1aa240d7058795c83d419510","userType":6,"introduction":"美股投资网","crmLevel":1,"crmLevelSwitch":0,"fanSize":21438,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"不眠夜！22小时都可以交易美股！纽约证券官宣！","digest":"美国纽约证券交易所周五宣布，计划将其全电子交易所的交易时间延长至每天 22 小时。根据新计划，纽约证券交易所 Arca 电子交易所的交易将于工作日凌晨 1:30 开始，并于美国东部时间晚上 11:30 结束，但须经监管机构批准。纽约证券交易所计划向美国证券交易委员会提交延长交易时间的最新规则。据美股投资网获悉，这里所说的延长交易时间，依然属于俗称的美股盘前、盘后交易。在正常交易时段（美东9点半-16点）之外进行美股交易，需要经过监管的批准。纽交所表示，延长交易时段的清算将继续由DTCC（美国存款信托与清算公司）进行，后者近期也已经宣布延长运营时段。美国纽约证券交易所（NYSE）是全球最大的证券交易所，也是美股投资网CEO兼创始人Ken之前的雇主，NYSE Arca 是买卖交易所交易基金和 8,000 多种美国上市证券的顶级平台。NYSE的母公司ICE洲际交易所表示，所有在美国上市的股票、ETF 和封闭式基金都将在电子交易所的 22 小时内开放交易。“纽约证交所市场主管凯文-泰瑞尔（Kevin Tyrrell）在一份声明中说：\"纽约证券交易所将美股交易时间延长至每周 5 天每天 22 小时的举措，凸显了美国资本市场的实力以及全球对我们上市证券日益增长的需求。“作为美国资本市场的管理者，纽约证券交易所很高兴能引领全球时区的投资者在交易所交易我们在美国上市的公司和基金\"。图片纽约证券交易所简介市值：NYSE的上市公司总市值通常高于任何其他交易所，包括纳斯达克（NASDAQ）和其他国际交易所。交易量：NYSE的日交易量和交易活动也非常活跃，尽管纳斯达克在某些时候的交易量可能超过NYSE。历史：NYSE成立于1817年，拥有悠久的历史，是全球最古老的证券交易所之一。全球影响力：由于其规模和影响力，NYSE在全球金融市场中扮演着重要角色，许多国际公司选择在此上市。美股周五收盘涨跌不一。","plainDigest":"美国纽约证券交易所周五宣布，计划将其全电子交易所的交易时间延长至每天 22 小时。根据新计划，纽约证券交易所 Arca 电子交易所的交易将于工作日凌晨 1:30 开始，并于美国东部时间晚上 11:30 结束，但须经监管机构批准。纽约证券交易所计划向美国证券交易委员会提交延长交易时间的最新规则。据美股投资网获悉，这里所说的延长交易时间，依然属于俗称的美股盘前、盘后交易。在正常交易时段（美东9点半-16点）之外进行美股交易，需要经过监管的批准。纽交所表示，延长交易时段的清算将继续由DTCC（美国存款信托与清算公司）进行，后者近期也已经宣布延长运营时段。美国纽约证券交易所（NYSE）是全球最大的证券交易所，也是美股投资网CEO兼创始人Ken之前的雇主，NYSE Arca 是买卖交易所交易基金和 8,000 多种美国上市证券的顶级平台。NYSE的母公司ICE洲际交易所表示，所有在美国上市的股票、ETF 和封闭式基金都将在电子交易所的 22 小时内开放交易。“纽约证交所市场主管凯文-泰瑞尔（Kevin Tyrrell）在一份声明中说：\"纽约证券交易所将美股交易时间延长至每周 5 天每天 22 小时的举措，凸显了美国资本市场的实力以及全球对我们上市证券日益增长的需求。“作为美国资本市场的管理者，纽约证券交易所很高兴能引领全球时区的投资者在交易所交易我们在美国上市的公司和基金\"。图片纽约证券交易所简介市值：NYSE的上市公司总市值通常高于任何其他交易所，包括纳斯达克（NASDAQ）和其他国际交易所。交易量：NYSE的日交易量和交易活动也非常活跃，尽管纳斯达克在某些时候的交易量可能超过NYSE。历史：NYSE成立于1817年，拥有悠久的历史，是全球最古老的证券交易所之一。全球影响力：由于其规模和影响力，NYSE在全球金融市场中扮演着重要角色，许多国际公司选择在此上市。美股周五收盘涨跌不一。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1729912651796,"gmtModify":1729913492870,"symbols":["ZK","NVDA","TSLA","IBRX","DJT"],"themeIds":["b9275bec7c49468194524435e3b90663"],"popularizeThemeFlag":false,"imageCount":4,"images":[{"url":"https://static.tigerbbs.com/806f2f374dbb5296036ed5038df05e58","width":"800","height":"414"},{"url":"https://static.tigerbbs.com/b1671db0e5ee7b6bb12ae7a579f57996","width":"931","height":"845"},{"url":"https://static.tigerbbs.com/26012d350bfbaa3446b660dd06c1df23","width":"1080","height":"1041"}],"repostCount":2,"viewCount":9481,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/364145188810816","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":1814,"displayRows":4,"foldSize":0,"authorId":"3478213283465426"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.300985728074024","cardData":[{"tweetId":"300985728074024","author":{"authorId":"3452938437060827","idStr":"3452938437060827","name":"牛唐","avatar":"https://static.tigerbbs.com/de2e2f2e2676bc8463b050f4e3ff17d2","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"fanSize":6599,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"正股跟随期权走，<a target=\"_blank\" href=\"https://laohu8.com/S/IBRX\">$ImmunityBio, Inc.(IBRX)$ </a>连续两天暴涨40%+，上周五放出5月3日到期的，6美元的看涨期权巨量，周一股价也是跟进上涨。<a target=\"_blank\" href=\"https://laohu8.com/S/CYCC\">$Cyclacel Pharmaceuticals(CYCC)$ </a><a target=\"_blank\" href=\"https://laohu8.com/S/BILI\">$哔哩哔哩(BILI)$ </a>","plainDigest":"正股跟随期权走，$ImmunityBio, Inc.(IBRX)$ 连续两天暴涨40%+，上周五放出5月3日到期的，6美元的看涨期权巨量，周一股价也是跟进上涨。$Cyclacel Pharmaceuticals(CYCC)$ $哔哩哔哩(BILI)$","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1714489008167,"gmtModify":1714489010343,"symbols":["CYCC","BILI","IBRX","09626"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":3526,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/300985728074024","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":167,"displayRows":4,"foldSize":0,"authorId":"3452938437060827"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.300481093652752","cardData":[{"tweetId":"300481093652752","author":{"authorId":"3566542729700747","idStr":"3566542729700747","name":"富悦守财哥","avatar":"https://static.tigerbbs.com/3e07739c09db1a94eebd11c78ad196e6","userType":1,"introduction":"","userGiftHeadFrame":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"fanSize":8,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"#守财哥的复盘日记20240427 <a href=\"https://laohu8.com/S/IBRX\">$ImmunityBio, Inc.(IBRX)$</a> 上周做对了票，判断也基本正确，却没赚到应该赚到的利润[流泪] [流泪] [流泪] 究其原因，终归贪念。跳空上涨后，做了坠落天使策略，出场虽早了点，毕竟是按交易计划进行。在震荡中空仓，忍不住做了其他票，等到天使👼回归时却没有了仓位，又舍不得出其他仓位，错过完美的赚大钱机会... 呜呼！交易的尽头，是耐心，是等待，是经得起诱惑的决绝...","plainDigest":"#守财哥的复盘日记20240427 $ImmunityBio, Inc.(IBRX)$ 上周做对了票，判断也基本正确，却没赚到应该赚到的利润[流泪] [流泪] [流泪] 究其原因，终归贪念。跳空上涨后，做了坠落天使策略，出场虽早了点，毕竟是按交易计划进行。在震荡中空仓，忍不住做了其他票，等到天使👼回归时却没有了仓位，又舍不得出其他仓位，错过完美的赚大钱机会... 呜呼！交易的尽头，是耐心，是等待，是经得起诱惑的决绝...","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1714379040725,"gmtModify":1714391667442,"symbols":["IBRX"],"themeIds":["5bfad02ab61749c8bfe6573ac7bbe8a3"],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/531b1dc42c9731a42d601440e3ecbeb4","width":"1086","height":"1712"}],"repostCount":0,"viewCount":4848,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/300481093652752","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"upFlag":true,"length":349,"displayRows":4,"foldSize":0,"authorId":"3566542729700747"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.300782791049448","cardData":[{"tweetId":"300782791049448","author":{"authorId":"4144880534816372","idStr":"4144880534816372","name":"Recyce","avatar":"https://community-static.tradeup.com/news/e8f47fb8cb49dae477aa9e2179f2d890","userType":1,"introduction":"","crmLevel":12,"crmLevelSwitch":0,"fanSize":102,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":53,"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"userFollowInvestorFlag":false,"ror":34.46,"showRor":true,"investmentPhilosophy":"守則：盡量不用..槓桿產品，包括期權、多倍ETF。","winRationPercentage":42.931937,"dataLabelList":[],"tradeVolumeEst":0},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"userFollowInvestorFlag":false,"digest":"20240430 Hea左几日，又睇睇个市先，SPX 明显系4月19日星期出左个底，4月22日ROC 2 系过去30日新高，算系一个入场信号，4月25日做左higher low ，跳跌低开即日补裂口兼高收，有明显大成交，如果冷静可以睇到呢个系几明显信号(但我都无睇到)，4月26日继续跳升亦无补裂口，呢此可见呢个反弹十分劲，寻晚亦企稳20EMA上，可以考虑积极入场。个股方面，IBRX系开市有大成交，于是想搏短炒大升，$10入但$9.5中止蚀走，但因为睇到有D机会可能再爆上，于是再入货，$9入场，止蚀系$7.5，重申呢D炒法，输既幅度一定系自己接受到、训得著，唔系下下训身去。而家我既杠杆系数系1.52，算系满仓有突了。 <a href=\"https://ttm.financial/S/IBRX\">$ImmunityBio, Inc.(IBRX)$</a><a href=\"https://ttm.financial/S/QQQ\">$纳指100ETF(QQQ)$ </a> <a href=\"https://ttm.financial/S/.SPX\">$标普500(.SPX)$ </a> ","plainDigest":"20240430 Hea左几日，又睇睇个市先，SPX 明显系4月19日星期出左个底，4月22日ROC 2 系过去30日新高，算系一个入场信号，4月25日做左higher low ，跳跌低开即日补裂口兼高收，有明显大成交，如果冷静可以睇到呢个系几明显信号(但我都无睇到)，4月26日继续跳升亦无补裂口，呢此可见呢个反弹十分劲，寻晚亦企稳20EMA上，可以考虑积极入场。个股方面，IBRX系开市有大成交，于是想搏短炒大升，$10入但$9.5中止蚀走，但因为睇到有D机会可能再爆上，于是再入货，$9入场，止蚀系$7.5，重申呢D炒法，输既幅度一定系自己接受到、训得著，唔系下下训身去。而家我既杠杆系数系1.52，算系满仓有突了。 $ImmunityBio, Inc.(IBRX)$$纳指100ETF(QQQ)$ $标普500(.SPX)$","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1714452808113,"gmtModify":1714452815253,"symbols":["IBRX","QQQ",".SPX"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":2104,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/300782791049448","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":568,"displayRows":4,"foldSize":0,"authorId":"4144880534816372"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.300633382895672","cardData":[{"tweetId":"300633382895672","author":{"authorId":"3586725352911887","idStr":"3586725352911887","name":"朝朝1030","avatar":"https://static.tigerbbs.com/16b89855701c2234789183a446e3d22e","userType":1,"introduction":"","crmLevel":2,"crmLevelSwitch":0,"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/IBRX\">$ImmunityBio, Inc.(IBRX)$ </a><a href=\"https://laohu8.com/S/IBRX\">$ImmunityBio, Inc.(IBRX)$ </a>","plainDigest":"$ImmunityBio, Inc.(IBRX)$ $ImmunityBio, Inc.(IBRX)$","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1714416218371,"gmtModify":1714416221372,"symbols":["IBRX"],"themeIds":["5bfad02ab61749c8bfe6573ac7bbe8a3"],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/d2c20d3d79f63619e8cbff7e00f3a9bc","width":"882","height":"1608"}],"repostCount":0,"viewCount":1864,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/300633382895672","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"upFlag":false,"length":48,"displayRows":4,"foldSize":0,"authorId":"3586725352911887"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.300632431411488","cardData":[{"tweetId":"300632431411488","author":{"authorId":"3586725352911887","idStr":"3586725352911887","name":"朝朝1030","avatar":"https://static.tigerbbs.com/16b89855701c2234789183a446e3d22e","userType":1,"introduction":"","crmLevel":2,"crmLevelSwitch":0,"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/IBRX\">$ImmunityBio, Inc.(IBRX)$ </a><a href=\"https://laohu8.com/S/IBRX\">$ImmunityBio, Inc.(IBRX)$ </a>","plainDigest":"$ImmunityBio, Inc.(IBRX)$ $ImmunityBio, Inc.(IBRX)$","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1714416101598,"gmtModify":1714416105407,"symbols":["IBRX"],"themeIds":["5bfad02ab61749c8bfe6573ac7bbe8a3"],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/59893db244cb17e12898f6495bfda341","width":"882","height":"1608"}],"repostCount":0,"viewCount":1899,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/300632431411488","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"upFlag":false,"length":48,"displayRows":4,"foldSize":0,"authorId":"3586725352911887"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.300625918632224","cardData":[{"tweetId":"300625918632224","author":{"authorId":"3586725352911887","idStr":"3586725352911887","name":"朝朝1030","avatar":"https://static.tigerbbs.com/16b89855701c2234789183a446e3d22e","userType":1,"introduction":"","crmLevel":2,"crmLevelSwitch":0,"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/IBRX\">$ImmunityBio, Inc.(IBRX)$ </a>","plainDigest":"$ImmunityBio, Inc.(IBRX)$","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1714414511564,"gmtModify":1714414515667,"symbols":["IBRX"],"themeIds":["5bfad02ab61749c8bfe6573ac7bbe8a3"],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/74e6645a12b8a1f62d2da6cd93a020b5","width":"882","height":"1608"}],"repostCount":0,"viewCount":1784,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/300625918632224","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":24,"displayRows":4,"foldSize":0,"authorId":"3586725352911887"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.300583488631064","cardData":[{"tweetId":"300583488631064","author":{"authorId":"3586725352911887","idStr":"3586725352911887","name":"朝朝1030","avatar":"https://static.tigerbbs.com/16b89855701c2234789183a446e3d22e","userType":1,"introduction":"","crmLevel":2,"crmLevelSwitch":0,"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/IBRX\">$ImmunityBio, Inc.(IBRX)$ </a>买入 8.88","plainDigest":"$ImmunityBio, Inc.(IBRX)$ 买入 8.88","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1714404097905,"gmtModify":1714404099319,"symbols":["IBRX"],"themeIds":["5bfad02ab61749c8bfe6573ac7bbe8a3"],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":2977,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/300583488631064","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":32,"displayRows":4,"foldSize":0,"authorId":"3586725352911887"}],"position":0}],"size":10},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":false,"hasAttachments":true,"id":"20758247","market":"us","labels":[],"media":"sec.gov","original_id":"AN132611026000030-IBRX","pdf_url":"","pub_time":1771885470000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","symbol":"IBRX","title":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","titleType":"年度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1326110/0001326110-26-000030-index.html","us_notice_code":"Form 10-K","us_title_en":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231.htm","primary":true,"translateUrl":"","linkName":"ibrx-20251231.htm","type":"10-K","id":"NTFILE8q42DYqZ1QUHoQST","market":"us","size":4370682},{"description":"EX-3.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231x10kexhibit31.htm","primary":false,"translateUrl":"","linkName":"ibrx-20251231x10kexhibit31.htm","type":"EX-3.1","id":"NTFILE5TGA32CcJsW1rH6S","market":"us","size":34312},{"description":"EX-10.34","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231x10kex1034.htm","primary":false,"translateUrl":"","linkName":"ibrx-20251231x10kex1034.htm","type":"EX-10.34","id":"NTFILE6hDp9e7wHdkZHSnn","market":"us","size":94235},{"description":"EX-21.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231x10kexhibit211.htm","primary":false,"translateUrl":"","linkName":"ibrx-20251231x10kexhibit211.htm","type":"EX-21.1","id":"NTFILE91Y687o9vPFMtjxj","market":"us","size":19019},{"description":"EX-23.1","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231x10kexhibit231.htm","primary":false,"translateUrl":"","linkName":"ibrx-20251231x10kexhibit231.htm","type":"EX-23.1","id":"NTFILE6b7M2yZQJN3wnNS9","market":"us","size":3165},{"description":"EX-23.2","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231x10kexhibit232.htm","primary":false,"translateUrl":"","linkName":"ibrx-20251231x10kexhibit232.htm","type":"EX-23.2","id":"NTFILEHMt9b8Dv96ZQhscE","market":"us","size":7647},{"description":"EX-31.1","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231x10kexhibit311.htm","primary":false,"translateUrl":"","linkName":"ibrx-20251231x10kexhibit311.htm","type":"EX-31.1","id":"NTFILEGvK2qZxz7xH4mEVp","market":"us","size":11266},{"description":"EX-31.2","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231x10kexhibit312.htm","primary":false,"translateUrl":"","linkName":"ibrx-20251231x10kexhibit312.htm","type":"EX-31.2","id":"NTFILE7M6j5gjRgLCdDbyH","market":"us","size":11251},{"description":"EX-32.1","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231x10kexhibit321.htm","primary":false,"translateUrl":"","linkName":"ibrx-20251231x10kexhibit321.htm","type":"EX-32.1","id":"NTFILEBZDuAG7GRSiyh6Sg","market":"us","size":5510},{"description":"EX-32.2","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231x10kexhibit322.htm","primary":false,"translateUrl":"","linkName":"ibrx-20251231x10kexhibit322.htm","type":"EX-32.2","id":"NTFILEcZhkscz7e7AWerBH","market":"us","size":5011},{"description":"IMAGE","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231_g1.jpg","primary":false,"translateUrl":"","linkName":"ibrx-20251231_g1.jpg","type":"GRAPHIC","id":"NTFILEsEYV12aAE6khzCwC","market":"us","size":73138},{"description":"IMAGE","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231_g10.jpg","primary":false,"translateUrl":"","linkName":"ibrx-20251231_g10.jpg","type":"GRAPHIC","id":"NTFILE9SkzTAAmqQoitwgi","market":"us","size":248392},{"description":"PERFORMANCE GRAPH","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231_g11.jpg","primary":false,"translateUrl":"","linkName":"ibrx-20251231_g11.jpg","type":"GRAPHIC","id":"NTFILE122yy1D13KDRYfzi","market":"us","size":90832},{"description":"IMAGE","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231_g2.jpg","primary":false,"translateUrl":"","linkName":"ibrx-20251231_g2.jpg","type":"GRAPHIC","id":"NTFILE3VZrC29oP2TneWhi","market":"us","size":97052},{"description":"IMAGE","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231_g3.jpg","primary":false,"translateUrl":"","linkName":"ibrx-20251231_g3.jpg","type":"GRAPHIC","id":"NTFILEBNLUm5kFkfGEu36r","market":"us","size":38808},{"description":"IMAGE","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231_g4.jpg","primary":false,"translateUrl":"","linkName":"ibrx-20251231_g4.jpg","type":"GRAPHIC","id":"NTFILE63E96iChUGgfUJxG","market":"us","size":348886},{"description":"IMAGE","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231_g5.jpg","primary":false,"translateUrl":"","linkName":"ibrx-20251231_g5.jpg","type":"GRAPHIC","id":"NTFILE6tHwH14XopXgfcXc","market":"us","size":390290},{"description":"IMAGE","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231_g6.jpg","primary":false,"translateUrl":"","linkName":"ibrx-20251231_g6.jpg","type":"GRAPHIC","id":"NTFILEAgXp9iyzbsy8MWSE","market":"us","size":925677},{"description":"IMAGE","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231_g7.jpg","primary":false,"translateUrl":"","linkName":"ibrx-20251231_g7.jpg","type":"GRAPHIC","id":"NTFILEAVpwA66CYnRaRnqJ","market":"us","size":60779},{"description":"IMAGE","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231_g8.jpg","primary":false,"translateUrl":"","linkName":"ibrx-20251231_g8.jpg","type":"GRAPHIC","id":"NTFILEJEHG6Emx4NgmXWiq","market":"us","size":118394},{"description":"IMAGE","seq":26,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231_g9.jpg","primary":false,"translateUrl":"","linkName":"ibrx-20251231_g9.jpg","type":"GRAPHIC","id":"NTFILEEaTjtQHJ6V3kKMrg","market":"us","size":1884972}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"年度报告","pubTime":"2026-02-24 06:24","pubTimestamp":1771885470,"title_zh":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20758253","market":"us","labels":[],"media":"sec.gov","original_id":"AN195004726001638-IBRX","pdf_url":"","pub_time":1771882106000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"IBRX","title":"Form 144 | ImmunityBio董事Christobel Selecky拟减持25000股，总价约21.75万美元","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/0001950047-26-001638-index.html","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"Form 144 | ImmunityBio董事Christobel Selecky拟减持25000股，总价约21.75万美元","gpt_en_title":"Form 144 | ImmunityBio Director Christobel Selecky proposes to sell 25,000 shares, with a total value of approximately $217,500","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000195004726001638/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEDADCiGFAuuqvLX6Q","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-02-24 05:28","pubTimestamp":1771882106,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","is_gpt_notice":1,"gpt_icon":1},{"cdn_pdf":false,"hasAttachments":true,"id":"20755645","market":"us","labels":[],"media":"sec.gov","original_id":"AN132611026000025-IBRX","pdf_url":"","pub_time":1771822800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"IBRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000025/0001326110-26-000025-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000025/ibrx-2026223x8kexhibit991.htm","primary":true,"translateUrl":"","linkName":"ibrx-2026223x8kexhibit991.htm","type":"EX-99.1","id":"NTFILEHZKArw3ehadhnWat","market":"us","size":173258},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000025/ibrx-20260223.htm","primary":false,"translateUrl":"","linkName":"ibrx-20260223.htm","type":"8-K","id":"NTFILEA5C8n9UXLBkb3soP","market":"us","size":30052},{"description":"IMMUNITYBIO LOGO","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000025/image_0a.jpg","primary":false,"translateUrl":"","linkName":"image_0a.jpg","type":"GRAPHIC","id":"NTFILE3GPpA85qBEwyMkqU","market":"us","size":2549}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-02-23 13:00","pubTimestamp":1771822800,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20745304","market":"us","labels":[],"media":"sec.gov","original_id":"AN132611026000018-IBRX","pdf_url":"","pub_time":1771390800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"IBRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000018/0001326110-26-000018-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000018/ibrx-20262188xkexhibit991.htm","primary":true,"translateUrl":"","linkName":"ibrx-20262188xkexhibit991.htm","type":"EX-99.1","id":"NTFILEDesSEA5rVMAEyvep","market":"us","size":39882},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000018/ibrx-20260218.htm","primary":false,"translateUrl":"","linkName":"ibrx-20260218.htm","type":"8-K","id":"NTFILE35FPtdBThQK1yCzW","market":"us","size":29414},{"description":"IMMUNITYBIO LOGO","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000018/immunitybio-logox2024xcolo.jpg","primary":false,"translateUrl":"","linkName":"immunitybio-logox2024xcolo.jpg","type":"GRAPHIC","id":"NTFILE2hBJqjebcZWJZN4c","market":"us","size":31902}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-02-18 13:00","pubTimestamp":1771390800,"title_zh":"Form 8-K - Current report","summary_en":"Item 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"项目8.01：其他事件；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20662573","market":"us","labels":[],"media":"sec.gov","original_id":"AN132611026000014-IBRX","pdf_url":"","pub_time":1769403600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"IBRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000014/0001326110-26-000014-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-10.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000014/ibrx-20261238xkexhibit101.htm","primary":true,"translateUrl":"","linkName":"ibrx-20261238xkexhibit101.htm","type":"EX-10.1","id":"NTFILEGZy7S8C1TBgKmDa1","market":"us","size":23351},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000014/ibrx-20260123.htm","primary":false,"translateUrl":"","linkName":"ibrx-20260123.htm","type":"8-K","id":"NTFILE8VNvuAGVCPnEKVLM","market":"us","size":29994}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-01-26 13:00","pubTimestamp":1769403600,"title_zh":"Form 8-K - Current report","summary_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第1.01项：签订重大最终协议；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20647362","market":"us","labels":[],"media":"sec.gov","original_id":"AN195004726000561-IBRX","pdf_url":"","pub_time":1768944584000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"IBRX","title":"Form 144 | IMMUNITYBIO董事 Christobel Selecky 拟减持25000股，总价约13.8万美元","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/0001950047-26-000561-index.html","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"Form 144 | IMMUNITYBIO董事 Christobel Selecky 拟减持25000股，总价约13.8万美元","gpt_en_title":"Form 144 | IMMUNITYBIO's Director Christobel Selecky proposes to sell 25000 shares, with a total value of approximately $138,000.","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000195004726000561/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEDTMsg39ZR8dGkJWM","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-01-21 05:29","pubTimestamp":1768944584,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","is_gpt_notice":1,"gpt_icon":1},{"cdn_pdf":false,"hasAttachments":true,"id":"20645615","market":"us","labels":[],"media":"sec.gov","original_id":"AN194984626000009-IBRX","pdf_url":"","pub_time":1768885200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"IBRX","title":"Form 144 | ImmunityBio高管兼董事 Simon Barry J.拟减持571967股，总价约590万美元","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/000194984626000009/0001949846-26-000009-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"Form 144 | ImmunityBio高管兼董事 Simon Barry J.拟减持571967股，总价约590万美元","gpt_en_title":"Form 144 | ImmunityBio's Officer and Director Simon Barry J. proposes to sell 571,967 Shares, with a total value of approximately $5.90 Million.","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000194984626000009/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEBQ1RcaLnuvpBRMYW","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-01-20 13:00","pubTimestamp":1768885200,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","is_gpt_notice":1,"gpt_icon":1},{"cdn_pdf":false,"hasAttachments":true,"id":"20640443","market":"us","labels":[],"media":"sec.gov","original_id":"AN195004726000516-IBRX","pdf_url":"","pub_time":1768539600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"IBRX","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/000195004726000516/0001950047-26-000516-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000195004726000516/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILE29sYHh4ZUWKwQXh7","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-01-16 13:00","pubTimestamp":1768539600,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20635254","market":"us","labels":[],"media":"sec.gov","original_id":"AN132611026000008-IBRX","pdf_url":"","pub_time":1768453200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"IBRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000008/0001326110-26-000008-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000008/ibrx-20261158xkexhibit991.htm","primary":true,"translateUrl":"","linkName":"ibrx-20261158xkexhibit991.htm","type":"EX-99.1","id":"NTFILE7jtw7uEqSXtTSYRT","market":"us","size":21400},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000008/ibrx-20260115.htm","primary":false,"translateUrl":"","linkName":"ibrx-20260115.htm","type":"8-K","id":"NTFILEBH1pVydd1iKSGNRL","market":"us","size":30539},{"description":"IMMUNITYBIO LOGO","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000008/immunitybio-logox2024xcoloa.jpg","primary":false,"translateUrl":"","linkName":"immunitybio-logox2024xcoloa.jpg","type":"GRAPHIC","id":"NTFILE5U3prMBFJxaPtTEg","market":"us","size":31902}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-01-15 13:00","pubTimestamp":1768453200,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20631592","market":"us","labels":[],"media":"sec.gov","original_id":"AN132611026000004-IBRX","pdf_url":"","pub_time":1768366800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"IBRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000004/0001326110-26-000004-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000004/ibrx-20261148xkexhibit991.htm","primary":true,"translateUrl":"","linkName":"ibrx-20261148xkexhibit991.htm","type":"EX-99.1","id":"NTFILEFcSgW4shVXcsfx63","market":"us","size":22145},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000004/ibrx-20260114.htm","primary":false,"translateUrl":"","linkName":"ibrx-20260114.htm","type":"8-K","id":"NTFILEB5q1TYYVGNpVDRSj","market":"us","size":33306},{"description":"EX-99.2","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000004/ibrx-20261148xkexhibit992.htm","primary":false,"translateUrl":"","linkName":"ibrx-20261148xkexhibit992.htm","type":"EX-99.2","id":"NTFILE2B5sy7CN2D5n2Fvc","market":"us","size":22612},{"description":"IMMUNITYBIO LOGO","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000004/immunitybio-logox2024xcoloa.jpg","primary":false,"translateUrl":"","linkName":"immunitybio-logox2024xcoloa.jpg","type":"GRAPHIC","id":"NTFILEAfV9JyXWjPx75qXU","market":"us","size":31902},{"description":"IMMUNITYBIO LOGO","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000004/immunitybio-logox2024xcolob.jpg","primary":false,"translateUrl":"","linkName":"immunitybio-logox2024xcolob.jpg","type":"GRAPHIC","id":"NTFILEDyZBDVsCncr2fsC9","market":"us","size":31902}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-01-14 13:00","pubTimestamp":1768366800,"title_zh":"Form 8-K - Current report","summary_en":"Item 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"项目8.01：其他事件；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20580199","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312525331244-IBRX","pdf_url":"","pub_time":1766535940000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"IBRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/0001193125-25-331244-index.html","us_notice_code":"Form 8-K","us_title_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-3.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000119312525331244/d61833dex31.htm","primary":true,"translateUrl":"","linkName":"d61833dex31.htm","type":"EX-3.1","id":"NTFILE5wn9Q63ra72RhjHU","market":"us","size":5815},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000119312525331244/d61833d8k.htm","primary":false,"translateUrl":"","linkName":"d61833d8k.htm","type":"8-K","id":"NTFILE3d9pjERon5F1on9x","market":"us","size":32268},{"description":"EX-5.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000119312525331244/d61833dex51.htm","primary":false,"translateUrl":"","linkName":"d61833dex51.htm","type":"EX-5.1","id":"NTFILE99BfwEG3xoeByXRQ","market":"us","size":9107},{"description":"EX-10.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000119312525331244/d61833dex101.htm","primary":false,"translateUrl":"","linkName":"d61833dex101.htm","type":"EX-10.1","id":"NTFILE7zNG17bKojG1yY8N","market":"us","size":14520},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000119312525331244/g61833g1223191314206.jpg","primary":false,"translateUrl":"","linkName":"g61833g1223191314206.jpg","type":"GRAPHIC","id":"NTFILE86JjTW2UH1EDimQs","market":"us","size":3107}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-12-24 08:25","pubTimestamp":1766535940,"title_zh":"Form 8-K - Current report","summary_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第1.01项：签订重大最终协议；项目8.01：其他事件；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20536193","market":"us","labels":[],"media":"sec.gov","original_id":"AN132611025000146-IBRX","pdf_url":"","pub_time":1765833953000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"IBRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/0001326110-25-000146-index.html","us_notice_code":"Form 8-K","us_title_en":"Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"8-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000146/ibrx-20251210.htm","primary":true,"translateUrl":"","linkName":"ibrx-20251210.htm","type":"8-K","id":"NTFILE6CzpzHSQpXYNAyHd","market":"us","size":32964}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-12-16 05:25","pubTimestamp":1765833953,"title_zh":"Form 8-K - Current report","summary_en":"Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第5.02项：董事或某些高级职员的离职；选举董事；若干人员的委任：若干人员的补偿安排；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20525570","market":"us","labels":[],"media":"sec.gov","original_id":"AN132611025000143-IBRX","pdf_url":"","pub_time":1765515600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"IBRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000143/0001326110-25-000143-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000143/ibrx-202512128xkexhibit991.htm","primary":true,"translateUrl":"","linkName":"ibrx-202512128xkexhibit991.htm","type":"EX-99.1","id":"NTFILEB5yJ4fNaqfqqVwK7","market":"us","size":24293},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000143/ibrx-20251212.htm","primary":false,"translateUrl":"","linkName":"ibrx-20251212.htm","type":"8-K","id":"NTFILEAyUjHmMNFuHqC7bF","market":"us","size":28173},{"description":"IMMUNITYBIO LOGO","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000143/immunitybio-logox2024xcolo.jpg","primary":false,"translateUrl":"","linkName":"immunitybio-logox2024xcolo.jpg","type":"GRAPHIC","id":"NTFILEFDzpSeZWPCBUZPPs","market":"us","size":31902}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-12-12 13:00","pubTimestamp":1765515600,"title_zh":"Form 8-K - Current report","summary_en":"Item 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"项目8.01：其他事件；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20371815","market":"us","labels":[],"media":"sec.gov","original_id":"AN132611025000138-IBRX","pdf_url":"","pub_time":1762318800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"IBRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/0001326110-25-000138-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-2025114x8kexhibit991.htm","primary":true,"translateUrl":"","linkName":"ibrx-2025114x8kexhibit991.htm","type":"EX-99.1","id":"NTFILEGdK2TmNKEiv1ZdUk","market":"us","size":130959},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-20251104.htm","primary":false,"translateUrl":"","linkName":"ibrx-20251104.htm","type":"8-K","id":"NTFILE2Vs52nXkAsFR7Tep","market":"us","size":30854},{"description":"IMMUNITYBIO LOGO","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/image_0.jpg","primary":false,"translateUrl":"","linkName":"image_0.jpg","type":"GRAPHIC","id":"NTFILE7WUdgmtrtNEUD5v2","market":"us","size":2549}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-11-05 13:00","pubTimestamp":1762318800,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20371801","market":"us","labels":[],"media":"sec.gov","original_id":"AN132611025000139-IBRX","pdf_url":"","pub_time":1762318800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"IBRX","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000139/0001326110-25-000139-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000139/ibrx-20250930.htm","primary":true,"translateUrl":"","linkName":"ibrx-20250930.htm","type":"10-Q","id":"NTFILED3qt9N3AECYVqGfX","market":"us","size":3282741},{"description":"EX-31.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000139/ibrx-2025930x10qexhibit311.htm","primary":false,"translateUrl":"","linkName":"ibrx-2025930x10qexhibit311.htm","type":"EX-31.1","id":"NTFILEF6npygf8KB3CMTL9","market":"us","size":11147},{"description":"EX-31.2","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000139/ibrx-2025930x10qexhibit312.htm","primary":false,"translateUrl":"","linkName":"ibrx-2025930x10qexhibit312.htm","type":"EX-31.2","id":"NTFILECkYvchTytivrjJ6o","market":"us","size":10915},{"description":"EX-32.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000139/ibrx-2025930x10qexhibit321.htm","primary":false,"translateUrl":"","linkName":"ibrx-2025930x10qexhibit321.htm","type":"EX-32.1","id":"NTFILEGticmPyxN73vEDpY","market":"us","size":5206},{"description":"EX-32.2","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000139/ibrx-2025930x10qexhibit322.htm","primary":false,"translateUrl":"","linkName":"ibrx-2025930x10qexhibit322.htm","type":"EX-32.2","id":"NTFILE7JmRACFFQZVL3R6L","market":"us","size":4951},{"description":"2025 PIPELINE","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000139/ibrx-20250930_g1.jpg","primary":false,"translateUrl":"","linkName":"ibrx-20250930_g1.jpg","type":"GRAPHIC","id":"NTFILEEo5m59DdPcpPo9Xz","market":"us","size":174354}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2025-11-05 13:00","pubTimestamp":1762318800,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.immunitybio.com","stockEarnings":[{"period":"1week","weight":-0.0323},{"period":"1month","weight":0.2829},{"period":"3month","weight":2.5551},{"period":"6month","weight":2.2269},{"period":"1year","weight":1.8931},{"period":"ytd","weight":3.2374}],"compareEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0429},{"period":"3month","weight":-0.0286},{"period":"6month","weight":0.0074},{"period":"1year","weight":0.2011},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ImmunityBio, Inc.于2002年10月7日在伊利诺伊州ZelleRx Corporation公司的名义下注册成立，于2010年1月22日，公司更名为Conkwest股份有限公司。ImmunityBio是一家领先的晚期免疫治疗公司，可激活先天和适应性免疫系统，以治疗肿瘤学和传染病领域内严重未满足的需求。公司是一家领先的临床剂型的现成自然杀伤细胞疗法生产商，记忆NK细胞，连同抗体细胞因子融合蛋白、白蛋白结合化学免疫调节剂和疫苗载体的综合平台。通过结合这些NK、巨噬细胞和T细胞激活平台，该公司相信ImmunityBio在免疫治疗领域处于领先地位，具有跨越多种肿瘤类型和传染病的后期临床开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.219152},{"month":2,"riseRate":0.545455,"avgChangeRate":0.075725},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.089174},{"month":4,"riseRate":0.5,"avgChangeRate":0.021643},{"month":5,"riseRate":0.4,"avgChangeRate":0.054052},{"month":6,"riseRate":0.3,"avgChangeRate":0.132356},{"month":7,"riseRate":0.4,"avgChangeRate":-0.029239},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.110134},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.03348},{"month":10,"riseRate":0.454545,"avgChangeRate":0.029893},{"month":11,"riseRate":0.636364,"avgChangeRate":0.121867},{"month":12,"riseRate":0.363636,"avgChangeRate":0.048951}],"exchange":"NASDAQ","name":"ImmunityBio, Inc.","nameEN":"ImmunityBio, Inc."},"aProfile":null}}}